REBECCA LEISTICO: Open Payments
NPI 1114695327 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$926 in 39 payments from 10 companies in 2025. Trend: 2023 $872 · 2024 $1,424 · 2025 $926
Food & beverage: $847Education: $79
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $417 |
| Ardelyx, Inc. | 3 | $143 |
| ABBVIE INC. | 9 | $139 |
| Madrigal Pharmaceuticals | 5 | $94 |
| Gilead Sciences, Inc. | 1 | $32 |
| Lilly USA, LLC | 1 | $24 |
| Amgen Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Celltrion USA Inc. | 1 | $15 |
| GENZYME CORPORATION | 1 | $15 |
Products named: TREMFYA, IBSRELA, REZDIFFRA, RINVOQ, SKYRIZI, CREON, OMVOH, UPLIZNA.
Industry payments across NE — which companies pay providers there.
